-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Chuangsheng Group announced that the first patient in the phase IIa clinical trial of TST001 has successfully completed the administration on August 17
Claudin 18.
Chuangsheng Group launched a phase I clinical trial of TST001 in the United States and China in August 2020, led by Professor Lin Shen from Peking University Cancer Hospital, to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TST001
The Phase IIa clinical trial of TST001 is an open, single-arm, multi-center study, which aims to further evaluate the safety, tolerability, and anti-tumor efficacy of TST001 in patients with multiple solid tumors expressed by Claudin 18.